Literature DB >> 2165570

Regions of the skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling.

T Tanabe1, K G Beam, B A Adams, T Niidome, S Numa.   

Abstract

It is thought that in skeletal muscle excitation-contraction (EC) coupling, the release of Ca2+ from the sarcoplasmic reticulum is controlled by the dihydropyridine (DHP) receptor in the transverse tubular membrane, where it serves as the voltage sensor. We have shown previously that injection of an expression plasmid carrying the skeletal muscle DHP receptor complementary DNA restores EC coupling and L-type calcium current that are missing in skeletal muscle myotubes from mutant mice with muscular dysgenesis. This restored coupling resembles normal skeletal muscle EC coupling, which does not require entry of extracellular Ca2+. By contrast, injection into dysgenic myotubes of an expression plasmid carrying the cardiac DHP receptor cDNA produces L-type calcium current and cardiac-type EC coupling, which does require entry of extracellular Ca2+. To identify the regions responsible for this important functional difference between the two structurally similar DHP receptors, we have expressed various chimaeric DHP receptor cDNAs in dysgenic myotubes. The results obtained indicate that the putative cytoplasmic region between repeats II and III of the skeletal muscle DHP receptor is an important determinant of skeletal-type EC coupling.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165570     DOI: 10.1038/346567a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  217 in total

1.  Involvement of the carboxy-terminus region of the dihydropyridine receptor beta1a subunit in excitation-contraction coupling of skeletal muscle.

Authors:  M Beurg; C A Ahern; P Vallejo; M W Conklin; P A Powers; R G Gregg; R Coronado
Journal:  Biophys J       Date:  1999-12       Impact factor: 4.033

2.  Calcium-induced calcium release in smooth muscle: loose coupling between the action potential and calcium release.

Authors:  M L Collier; G Ji; Y Wang; M I Kotlikoff
Journal:  J Gen Physiol       Date:  2000-05       Impact factor: 4.086

3.  Triad proteins and intracellular Ca2+ transients during development of human skeletal muscle cells in aneural and innervated cultures.

Authors:  H Tanaka; T Furuya; N Kameda; T Kobayashi; H Mizusawa
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

4.  Alternatively spliced alpha(1G) (Ca(V)3.1) intracellular loops promote specific T-type Ca(2+) channel gating properties.

Authors:  J Chemin; A Monteil; E Bourinet; J Nargeot; P Lory
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

5.  Kinetics of inactivation and restoration from inactivation of the L-type calcium current in human myotubes.

Authors:  C Harasztosi; I Sipos; L Kovacs; W Melzer
Journal:  J Physiol       Date:  1999-04-01       Impact factor: 5.182

6.  Two mechanisms for termination of individual Ca2+ sparks in skeletal muscle.

Authors:  A Lacampagne; M G Klein; C W Ward; M F Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

7.  Effects of imperatoxin A on local sarcoplasmic reticulum Ca(2+) release in frog skeletal muscle.

Authors:  A Shtifman; C W Ward; J Wang; H H Valdivia; M F Schneider
Journal:  Biophys J       Date:  2000-08       Impact factor: 4.033

8.  A cardiac dihydropyridine receptor II-III loop peptide inhibits resting Ca(2+) sparks in ferret ventricular myocytes.

Authors:  Y Li; D M Bers
Journal:  J Physiol       Date:  2001-11-15       Impact factor: 5.182

9.  Two domains in dihydropyridine receptor activate the skeletal muscle Ca(2+) release channel.

Authors:  M Stange; A Tripathy; G Meissner
Journal:  Biophys J       Date:  2001-09       Impact factor: 4.033

10.  Charge movement and transcription regulation of L-type calcium channel alpha(1S) in skeletal muscle cells.

Authors:  Zhenlin Zheng; Zhong-Min Wang; Osvaldo Delbono
Journal:  J Physiol       Date:  2002-04-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.